Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Cash from Financing Activities (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Cash from Financing Activities for 10 consecutive years, with -$67000.0 as the latest value for Q3 2025.

  • Quarterly Cash from Financing Activities fell 138.07% to -$67000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $148000.0 through Dec 2025, down 99.92% year-over-year, with the annual reading at $148000.0 for FY2025, 99.92% down from the prior year.
  • Cash from Financing Activities hit -$67000.0 in Q3 2025 for Rocket Pharmaceuticals, down from $215000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $189.5 million in Q3 2023 to a low of -$67000.0 in Q3 2025.
  • Historically, Cash from Financing Activities has averaged $32.6 million across 5 years, with a median of $1.4 million in 2024.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 46664.45% in 2024 and later crashed 138.07% in 2025.
  • Year by year, Cash from Financing Activities stood at $1.1 million in 2021, then skyrocketed by 9445.77% to $108.4 million in 2022, then crashed by 99.64% to $391000.0 in 2023, then surged by 46664.45% to $182.8 million in 2024, then crashed by 100.04% to -$67000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for RCKT at -$67000.0 in Q3 2025, $215000.0 in Q2 2025, and $182.8 million in Q4 2024.